Q3 FY26 results: PAT jumps 65% YoY, amalgamation scheme effective

Pat Growth 25pctResults RestatedExceptional ItemEmphasis Of MatterResults View source PDF Explain this filing

VIYASH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.0%Reaction day

₹209.00

prior close

₹207.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.8%-2.2% vs market

Pharmaceuticals peers, median of 159sector-0.6%-2.4% vs sector

On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.6

10m

-2.6

15m

-2.4

30m

-2.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.0-0.8-2.2-0.6-2.4

Next day

-0.5+1.8-2.3+1.2-1.7

-1.9+2.8-4.7+1.8-3.6

+3.4+2.3+1.1+1.3+2.1

+6.9+1.8+5.1+0.5+6.4

+3.3+0.3+3.1+0.0+3.3

+5.3+0.5+4.7-0.2+5.4

15d

+2.4-2.5+5.0-2.7+5.2

-2.8-6.3+3.6-4.6+1.8

-6.7-8.0+1.2-7.4+0.6

+5.5+8.3-2.8+2.6+2.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Viyash Scientific reported Q3 FY26 consolidated revenue of Rs 8,584.10 million, up about 11% YoY, and PAT of Rs 485.20 million, up 65% YoY. 9M FY26 PAT surged to Rs 1,582.70 million from Rs 479.50 million. All prior period figures restated to give effect to the Composite Scheme of Amalgamation, which became effective December 16, 2025. The Board also approved a new ESOP 2026 covering up to 1.34 crore options, and made changes to senior management personnel.

Likely market impact

Strong profit growth driven by amalgamation consolidation. Restated numbers and new ESOP signal post-merger integration. Watch for potential dilution from scheme shares and ESOPs.